DexCom, Inc. (NASDAQ:DXCM) – Equities research analysts at Northcoast Research issued their Q1 2018 earnings per share estimates for DexCom in a research note issued on Sunday. Northcoast Research analyst E. Snyder forecasts that the medical device company will post earnings of ($0.30) per share for the quarter. Northcoast Research currently has a “Buy” rating on the stock. Northcoast Research also issued estimates for DexCom’s Q2 2018 earnings at ($0.18) EPS, Q3 2018 earnings at ($0.03) EPS, Q4 2018 earnings at ($0.01) EPS and FY2018 earnings at ($0.52) EPS.
A number of other equities analysts have also recently weighed in on the company. ValuEngine cut DexCom from a “hold” rating to a “sell” rating in a report on Wednesday. Zacks Investment Research cut DexCom from a “hold” rating to a “sell” rating in a report on Friday, March 2nd. Canaccord Genuity increased their target price on DexCom from $62.00 to $71.00 and gave the stock a “buy” rating in a research note on Wednesday, February 28th. Oppenheimer set a $67.00 target price on DexCom and gave the stock a “buy” rating in a research note on Wednesday, February 28th. Finally, BidaskClub lowered DexCom from a “buy” rating to a “hold” rating in a research note on Tuesday, February 27th. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and thirteen have issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $65.97.
DexCom (DXCM) opened at $59.84 on Wednesday. The company has a debt-to-equity ratio of 0.78, a quick ratio of 5.04 and a current ratio of 5.36. DexCom has a twelve month low of $42.62 and a twelve month high of $86.32.
DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Tuesday, February 27th. The medical device company reported $0.10 earnings per share for the quarter, topping analysts’ consensus estimates of $0.03 by $0.07. The business had revenue of $221.00 million during the quarter, compared to analysts’ expectations of $217.82 million. DexCom had a negative return on equity of 13.99% and a negative net margin of 6.99%.
A number of hedge funds have recently bought and sold shares of DXCM. JPMorgan Chase & Co. raised its position in DexCom by 143.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,358,507 shares of the medical device company’s stock valued at $107,170,000 after purchasing an additional 7,738,678 shares in the last quarter. Janus Henderson Group PLC raised its position in DexCom by 29.2% in the 3rd quarter. Janus Henderson Group PLC now owns 8,819,825 shares of the medical device company’s stock valued at $431,510,000 after purchasing an additional 1,991,094 shares in the last quarter. Brown Advisory Inc. raised its position in DexCom by 57.2% in the 3rd quarter. Brown Advisory Inc. now owns 4,165,522 shares of the medical device company’s stock valued at $203,798,000 after purchasing an additional 1,515,134 shares in the last quarter. Bridger Management LLC acquired a new stake in DexCom in the 4th quarter valued at about $48,826,000. Finally, OppenheimerFunds Inc. raised its position in DexCom by 96.5% in the 4th quarter. OppenheimerFunds Inc. now owns 1,495,535 shares of the medical device company’s stock valued at $85,829,000 after purchasing an additional 734,325 shares in the last quarter.
In other DexCom news, insider Terrance H. Gregg sold 10,000 shares of the stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $56.86, for a total value of $568,600.00. Following the sale, the insider now owns 484,559 shares of the company’s stock, valued at approximately $27,552,024.74. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Richard Doubleday sold 1,638 shares of the stock in a transaction dated Friday, February 23rd. The shares were sold at an average price of $56.32, for a total value of $92,252.16. Following the completion of the sale, the executive vice president now directly owns 65,049 shares in the company, valued at approximately $3,663,559.68. The disclosure for this sale can be found here. Insiders sold a total of 34,153 shares of company stock worth $1,953,327 in the last ninety days. 1.70% of the stock is owned by corporate insiders.
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.